rF1V-1018

Phase 2

Dynavax Technologies Corporation (DVAX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

DVAXPhase 2$1.8B

rF1V-1018 Phase 2 Est. Readout

rF1V-1018• Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis148

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

View Full Landscape

Drug Information

Target Indication

Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Clinical Trial

NCT07207408

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

DVAX

Dynavax Technologies Corporation

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

HEPLISAV-BPhase 3

Chronic Kidney Disease

HEPLISAVPhase 3

Hepatitis B

FendrixPhase 3

End Stage Renal Disease

Engerix-BPhase 3

Hepatitis B

RituxanPhase 2

Non-Hodgkin's Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts